Integra LifeSciences Holdings Corporation (IART) Posts Q3, Guides Q4 Lower; Completes $2.1B Refi

Integra LifeSciences (IART) reported Q3 revenue of $411.2M, up 2.3% YoY, and adjusted EPS of $0.59. The company guided Q4 revenue to $413M–$433M and adjusted EPS to $0.61–$0.71, reflecting a decline of up to 5.2% YoY. It also completed a $2.1B debt refinancing.

Original reporting
Published Oct 21, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra LifeSciences Holdings Corporation (IART) Posts Q3, Guides Q4 Lower; Completes $2.1B Refi — source image
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The Q3 earnings beat was modest, but the lowered Q4 outlook and sizable refinancing raise concerns about near‑term growth.

02

Market read

First report of Integra's Q3 results and guidance, with a $2.1B debt refinance, likely to move the stock.

03

What to watch

Potential upside from a faster recovery in Cincinnati and margin expansion if cost controls succeed.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences is a medical device company focused on neurosurgery and tissue reconstruction.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences posted Q3 results and lowered Q4 guidance while completing a $2.1B debt refinancing.

Expected impact

likely downside as investors price in weaker Q4 revenue and earnings.

Evidence & confidence

Revenue guidance narrowed and lowered; EPS guidance also reduced, indicating softer demand in Tissue Reconstruction.

Market effects

May weigh on other medical device and tissue reconstruction firms.

Limited to U.S. healthcare equities.

Low; impact confined to sector.

Counterpoint

If the refinancing improves balance sheet flexibility, the stock could rebound on the back of lower financing costs.

Key entities

  • Integra LifeSciences Holdings Corporation

    Issuer of the earnings and refinancing announcement.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.